Drug Profile
IPL 344
Alternative Names: IPL-344Latest Information Update: 27 Jan 2024
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Developer Immunity Pharma
- Class Anti-inflammatories; Peptides
- Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Apoptosis inhibitors; Proto oncogene protein c akt modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
Most Recent Events
- 17 Jan 2024 Efficacy, adverse events and pharmacodynamic data from a phase IIa trial in Amyotrophic lateral sclerosis released by Immunity Pharma
- 17 Jan 2024 Immunity Pharma plans a pivotal trial for Amyotrophic lateral sclerosis
- 03 Dec 2023 Immunity Pharma suspended phase I/II clinical trials in Amyotrophic lateral sclerosis in Israel (IV) due to IPL 344 shortage and may resume once drug supply is available (NCT03652805)